Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

FDA Sends Warning Letters To Makers Of Unapproved Prescription Narcotics

Posted by Chrissie Cole
Wednesday, April 01, 2009 10:11 AM EST
Category: Major Medical
Tags: FDA and Prescription Drugs, Phamrmaceutical Industry, Drugs, Narcotics, Morphine, Oxycodone


IMAGE SOURCE: © iStockPhoto / pills / author: FotografiaBasica

The U.S. Food and Drug Administration (FDA) has sent warning letters to nine drug companies to stop manufacturing 14 unapproved narcotic drugs, as part of the FDA's initiative to crackdown on unapproved-drugs.

The warning letters notified the companies they may be subject to legal action if they do not stop manufacturing and distributing "unapproved narcotic prescription products" that include high concentrate morphine sulfate oral solutions and immediate release tablets containing morphine sulfate, hydromorphone or oxycodone. Oxycodone capsules are not included in this action.

The agency has no way of knowing whether these drugs are safe, if they contain labeled ingredients, or if they carry correct dosages, says Deborah M. Autor, J.D., FDA's Center for Drug Evaluation and Research (CDER).

The FDA began its unapproved-drug crackdown in June 2006. Since that time, 200 firms and 900 drug products have been subject to FDA actions.

According to the FDA, an estimated 2 percent of prescriptions in the United States are filled with unapproved drugs.

The firms subject to today's FDA warning letters are:

Boehringer Ingelheim Roxane, Inc., Columbus, Ohio; Cody Laboratories, Inc., Cody, Wyoming; Glenmark Pharmaceuticals Inc., Mahwah, N.J.; Lannett Company, Inc., Philadelphia; Lehigh Valley Technologies, Inc., Allentown, Pa.; Mallinckrodt Inc. Pharmaceuticals Group, St. Louis; Physicians Total Care Inc., Tulsa, Okla.; Roxane Laboratories Inc., Columbus, Ohio; and Xanodyne Pharmaceuticals Inc., Newport, Ky.

Copies of the warning letters can be found on the FDA Web site.

Those people who rely on narcotics for pain relief will continue to have access to FDA-approved narcotic products that have been evaluated and determined to be safe and effective.

While there is no specific safety concerns, says Autor, lack of assurance of purity and quality raises concerns. These manufacturers have failed to submit data to the FDA that guarantees the safety and purity of their products.”

Firms have 15 days to reply to the warning. Manufacturers have 60 days to stop making these drugs and 90 days to stop shipping existing products. #

1 Comment

Anonymous User
Posted by Joan Petty
Friday, April 03, 2009 12:37 AM EST

The FDA can write all the letters in the world and can yell and scream all they want.
The crux of the matter is there is NO LAW FOR A REMEDY FOR ANYONE BECAUSE THERE IS NO PRODUCT LIABILITY FOR A DEFECT PRESCRIPTION DRUG. if the drug is preapproved by the FDA and has already been on the market. The generic can be produced and the manufacturer has a shield of protection.

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes